New hope to shield hearts from cancer drug damage
NCT ID NCT07233499
Summary
This study is testing if a blood pressure drug called nebivolol can protect the heart from damage caused by trastuzumab, a life-saving breast cancer treatment. It will involve 56 women with HER2-positive breast cancer who are starting trastuzumab therapy. Researchers will measure heart function and quality of life to see if nebivolol safely reduces heart-related side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Institute- Cairo University- Egypt
RECRUITINGCairo, Egypt
Contact Phone: •••-•••-••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.